Insider Selling: Cerus (NASDAQ:CERS) Insider Sells $48,712.35 in Stock

Cerus Corporation (NASDAQ:CERS) insider Richard Benjamin sold 24,235 shares of Cerus stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $2.01, for a total value of $48,712.35. Following the sale, the insider owned 919,527 shares of the company’s stock, valued at approximately $1,848,249.27. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Cerus Stock Up 1.1%

Shares of NASDAQ CERS opened at $1.79 on Thursday. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $2.30 and a 200-day moving average of $1.86. The firm has a market capitalization of $343.98 million, a price-to-earnings ratio of -22.38 and a beta of 1.51. Cerus Corporation has a 12 month low of $1.12 and a 12 month high of $2.96.

Cerus (NASDAQ:CERS) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. Sell-side analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Cibc World Markets Corp bought a new stake in shares of Cerus in the 4th quarter worth approximately $25,000. MML Investors Services LLC bought a new position in shares of Cerus during the 4th quarter valued at $37,000. Caitong International Asset Management Co. Ltd raised its position in Cerus by 68.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 7,603 shares during the period. Bingham Private Wealth LLC purchased a new position in Cerus in the 4th quarter worth $40,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Cerus in the third quarter worth $31,000. 78.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CERS. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a report on Monday, January 12th. Wall Street Zen downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.